Vaccination against SARS-CoV-2: prospective longitudinal study in the employees of AV4 in Fermo Background: The SARS-Cov-2 epidemic has had a significant impact on society by upsetting our social and working habits, and jeopardizing the stability of our National Health System. To counter the epidemic, the Ministry of Health has started a vaccination campaign whose results and indications are continuously updated by scientific evidence Objective: the study aims to evaluate the effectiveness of the Pzifer-Biontech vaccination through antibody titration at 120 and 180 days and to highlight whether there is a correlation between sex, smoking habit, comorbidities and the appearance of adverse events after the first and second dose. Methods: a prospective longitudinal study was carried out from 25/05/2021 to 30/09/2021 by measuring the Ig at 120 and 180 days from the completion of the vaccination cycle and the administration of a questionnaire for post-vaccination clinical monitoring in which highlight any adverse events, demographic, occupational and anamnestic data. The study population is represented by Av4 health and non-medical employees. Results: The sample was made up of 800 subjects: 568 (81%) women and 232 (29%) men. 41 employees (5.1%) are aged between 20 and 30, 157 (19.6%) between 31 and 40, 216 (27%) between 41 and 50, 309 (38.7%) between 21 and 60 and 77 (9.6%) over 61 years. Those who had had a positive serologic before the first dose maintained an Ig mean of 1718 at 120 days and 1524 at 180 days compared to 838 at 120 days and 537 at 180 days of those who did not have positive serologic before the first dose. In non-smokers, the average Ig is 949 at 120 days and 657 at 180 days compared to 787 at 120 days and 493 at 180 days in smokers. Men between the ages of 20 and 30 have an Ig average of 1063 at 120 days and 858, 3 at 180 days, while those over 61 have an average Ig of 710 at 120 days and 585 at 180 days. 87.6% of women reported adverse events while 71% of men reported adverse events. 84.4% of subjects with comorbidities reported adverse events, while 82.10% of subjects without comorbidities reported adverse events. reported adverse events. Similar situation for smokers: Smokers who reported adverse events are 84.4% while non-smokers who report adverse events are 82.3%. As for women, similar situation: Those aged between 20 and 30 have an average Ig of 1198 at 120 days and 868 at 180 days, while those over 61 have an average Ig of 776 a 120 days and 585 to 180 days. Conclusions: There could be a correlation between smoking habit and humoral response (non-smokers had on average a higher antibody titer than smokers) and between age and immune response even here the average of circulating Ig in subjects aged 20 -30 years compared to those over 61 years of age. In all three situations we can see the tendency of the Ig average to decrease over time. Regarding the adverse events, the numerical differences are too subtle to be able to state that there is a correlation between sex, smoking, comorbidities and the occurrence of adverse events.
La vaccinazione anti SARS-CoV-2: studio longitudinale prospettivo nel personale dipendente dell’AV4 di Fermo Background: L’epidemia da Sars-Cov-2 ha avuto un notevole impatto sulla società stravolgendo le nostre abitudini di vita sociale e lavorativa, e mettendo a repentaglio la stabilità del nostro Sistema Sanitario Nazionale. Per contrastare l’epidemia il Ministero della Salute ha dato inizio ad una campagna vaccinale i cui esiti ed indicazioni vengono aggiornati continuamente dalle evidenze scientifiche Obiettivo: lo studio si propone di valutare l’efficacia della vaccinazione Pzifer-Biontech attraverso la titolazione anticorpale a 120 e 180 giorni e di evidenziare se vi è correlazione tra sesso, abitudine al fumo, comorbilità e comparsa di eventi avversi dopo la prima e seconda dose. Metodi: è stato realizzato uno studio di tipo longitudinale prospettico dal 25/05/2021 al 30/09/2021 mediante il dosaggio delle Ig a 120 e 180 giorni dal completamento del ciclo vaccinale e somministrazione di un questionario per il monitoraggio clinico post vaccinazione in cui evidenziare eventuali eventi avversi, dati demografici, occupazionali e anamnestici. La popolazione in studio è rappresentata da dipendenti dell’Av4 sanitari e non Risultati: Il campione è composto da 800 soggetti: 568 (81%) donne e 232 (29%) uomini. 41 dipendenti (5,1%) hanno un’età compresa tra 20 e 30 anni, 157 (19,6%) tra 31 e 40, 216 (27%) tra 41 e 50, 309 (38,7%) tra 21 e 60 e 77 (9,6%) più di 61 anni. Chi aveva avuto un sierologico positivo prima della prima dose ha mantenuto una media di Ig di 1718 a 120 giorni e 1524 a 180 giorni contro 838 a 120 giorni e 537 a 180 giorni di coloro che non hanno avuto sierologico positivo prima della prima dose. Nei non fumatori la media delle Ig è 949 a 120 giorni e 657 a 180 giorni contro 787 a 120 giorni e 493 a 180 giorni nei fumatori. Gli uomini di età compresa tra 20 e 30 anni hanno una media di Ig 1063 a 120 giorni e 858, 3 a 180 giorni, mentre chi ha più di 61 anni ha una media di Ig di 710 a 120 giorni e 585 a 180 giorni. L’87,6% delle donne ha riferito eventi avversi mentre il 71% degli uomini ha lamentato eventi avversi.L’84,4% dei soggetti con comorbilità ha riferito eventi avversi, mentre l’82,10% dei soggetti senza comorbilità ha riferito eventi avversi. Situazione analoga per i fumatori: I fumatori che hanno riferito eventi avversi sono 84,4% mentre i non fumatori a lamentare eventi avversi sono l’82,3%. Per quanto riguarda le donne situazione analoga: Chi ha un’età compresa tra 20 e 30 anni ha una media di Ig di 1198 a 120 giorni e 868 a 180 giorni, mentre chi ha più di 61 anni ha una media di Ig di 776 a 120 giorni e 585 a 180 giorni. Conclusioni: Vi potrebbe essere correlazione tra abitudine al fumo e risposta umorale (i non fumatori avevano in media un titolo anticorpale più alto rispetto ai fumatori) e tra età e risposta immunitaria anche qua la media delle Ig circolanti in soggetti di fascia d’età 20-30 anni rispetto a quelli di età superiore a 61 anni. In tutte e tre le situazioni si vede la tendenza della media delle Ig a scendere nel tempo. Per quanto riguarda gli eventi avversi le differenze numeriche sono troppo sottili per poter affermare che vi è correlazione tra sesso, abitudine al fumo, comorbilità e comparsa di eventi avversi.
La vaccinazione anti SARS-CoV-2: studio longitudinale prospettivo nel personale dipendente dell’AV4 di Fermo
ANGELINI, ELISA
2020/2021
Abstract
Vaccination against SARS-CoV-2: prospective longitudinal study in the employees of AV4 in Fermo Background: The SARS-Cov-2 epidemic has had a significant impact on society by upsetting our social and working habits, and jeopardizing the stability of our National Health System. To counter the epidemic, the Ministry of Health has started a vaccination campaign whose results and indications are continuously updated by scientific evidence Objective: the study aims to evaluate the effectiveness of the Pzifer-Biontech vaccination through antibody titration at 120 and 180 days and to highlight whether there is a correlation between sex, smoking habit, comorbidities and the appearance of adverse events after the first and second dose. Methods: a prospective longitudinal study was carried out from 25/05/2021 to 30/09/2021 by measuring the Ig at 120 and 180 days from the completion of the vaccination cycle and the administration of a questionnaire for post-vaccination clinical monitoring in which highlight any adverse events, demographic, occupational and anamnestic data. The study population is represented by Av4 health and non-medical employees. Results: The sample was made up of 800 subjects: 568 (81%) women and 232 (29%) men. 41 employees (5.1%) are aged between 20 and 30, 157 (19.6%) between 31 and 40, 216 (27%) between 41 and 50, 309 (38.7%) between 21 and 60 and 77 (9.6%) over 61 years. Those who had had a positive serologic before the first dose maintained an Ig mean of 1718 at 120 days and 1524 at 180 days compared to 838 at 120 days and 537 at 180 days of those who did not have positive serologic before the first dose. In non-smokers, the average Ig is 949 at 120 days and 657 at 180 days compared to 787 at 120 days and 493 at 180 days in smokers. Men between the ages of 20 and 30 have an Ig average of 1063 at 120 days and 858, 3 at 180 days, while those over 61 have an average Ig of 710 at 120 days and 585 at 180 days. 87.6% of women reported adverse events while 71% of men reported adverse events. 84.4% of subjects with comorbidities reported adverse events, while 82.10% of subjects without comorbidities reported adverse events. reported adverse events. Similar situation for smokers: Smokers who reported adverse events are 84.4% while non-smokers who report adverse events are 82.3%. As for women, similar situation: Those aged between 20 and 30 have an average Ig of 1198 at 120 days and 868 at 180 days, while those over 61 have an average Ig of 776 a 120 days and 585 to 180 days. Conclusions: There could be a correlation between smoking habit and humoral response (non-smokers had on average a higher antibody titer than smokers) and between age and immune response even here the average of circulating Ig in subjects aged 20 -30 years compared to those over 61 years of age. In all three situations we can see the tendency of the Ig average to decrease over time. Regarding the adverse events, the numerical differences are too subtle to be able to state that there is a correlation between sex, smoking, comorbidities and the occurrence of adverse events.I documenti in UNITESI sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/20.500.12075/995